1. Home
  2. CRSP vs ATMU Comparison

CRSP vs ATMU Comparison

Compare CRSP & ATMU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • ATMU
  • Stock Information
  • Founded
  • CRSP 2013
  • ATMU 1958
  • Country
  • CRSP Switzerland
  • ATMU United States
  • Employees
  • CRSP N/A
  • ATMU N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • ATMU Auto Parts:O.E.M.
  • Sector
  • CRSP Health Care
  • ATMU Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • ATMU Nasdaq
  • Market Cap
  • CRSP 3.4B
  • ATMU 3.4B
  • IPO Year
  • CRSP 2016
  • ATMU 2023
  • Fundamental
  • Price
  • CRSP $40.53
  • ATMU $42.20
  • Analyst Decision
  • CRSP Buy
  • ATMU Buy
  • Analyst Count
  • CRSP 19
  • ATMU 5
  • Target Price
  • CRSP $77.13
  • ATMU $43.80
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • ATMU 575.6K
  • Earning Date
  • CRSP 02-19-2025
  • ATMU 02-12-2025
  • Dividend Yield
  • CRSP N/A
  • ATMU 0.47%
  • EPS Growth
  • CRSP N/A
  • ATMU 3.84
  • EPS
  • CRSP N/A
  • ATMU 2.15
  • Revenue
  • CRSP $202,829,000.00
  • ATMU $1,662,600,000.00
  • Revenue This Year
  • CRSP N/A
  • ATMU $4.11
  • Revenue Next Year
  • CRSP $724.16
  • ATMU $3.24
  • P/E Ratio
  • CRSP N/A
  • ATMU $19.63
  • Revenue Growth
  • CRSP 19.31
  • ATMU 3.04
  • 52 Week Low
  • CRSP $36.52
  • ATMU $21.09
  • 52 Week High
  • CRSP $91.10
  • ATMU $45.43
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.09
  • ATMU 67.46
  • Support Level
  • CRSP $36.52
  • ATMU $38.42
  • Resistance Level
  • CRSP $40.99
  • ATMU $42.10
  • Average True Range (ATR)
  • CRSP 1.78
  • ATMU 0.90
  • MACD
  • CRSP 0.23
  • ATMU 0.42
  • Stochastic Oscillator
  • CRSP 51.68
  • ATMU 93.17

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About ATMU Atmus Filtration Technologies Inc.

Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. It designs and manufactures advanced filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. Atmus offers products for first-fit and aftermarket applications including air filters, fuel filters, fuel water separators, lube filters, hydraulic filters, coolants, fuel additives, and other filtration systems to original equipment manufacturers, dealers/distributors, and end-users.

Share on Social Networks: